Graphene Investments SAS Purchases 3,300 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Graphene Investments SAS increased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 14.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 25,700 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,300 shares during the period. Graphene Investments SAS’s holdings in Jazz Pharmaceuticals were worth $3,095,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Jazz Pharmaceuticals by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 6,379,053 shares of the specialty pharmaceutical company’s stock valued at $825,705,000 after purchasing an additional 29,960 shares in the last quarter. Ameriprise Financial Inc. boosted its position in Jazz Pharmaceuticals by 4.6% in the third quarter. Ameriprise Financial Inc. now owns 1,299,612 shares of the specialty pharmaceutical company’s stock valued at $168,222,000 after buying an additional 57,717 shares in the last quarter. Polaris Capital Management LLC grew its stake in shares of Jazz Pharmaceuticals by 2.2% during the fourth quarter. Polaris Capital Management LLC now owns 1,267,460 shares of the specialty pharmaceutical company’s stock worth $155,898,000 after buying an additional 27,100 shares during the last quarter. Pacer Advisors Inc. increased its holdings in shares of Jazz Pharmaceuticals by 28.1% during the fourth quarter. Pacer Advisors Inc. now owns 1,023,706 shares of the specialty pharmaceutical company’s stock worth $125,916,000 after buying an additional 224,865 shares in the last quarter. Finally, Baupost Group LLC MA lifted its stake in shares of Jazz Pharmaceuticals by 23.7% in the 4th quarter. Baupost Group LLC MA now owns 833,696 shares of the specialty pharmaceutical company’s stock valued at $102,545,000 after acquiring an additional 160,000 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Trading Down 1.5 %

JAZZ traded down $1.56 during trading on Wednesday, reaching $103.53. 304,674 shares of the stock traded hands, compared to its average volume of 690,964. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 1.38. The stock’s 50-day moving average is $108.80 and its 200 day moving average is $116.44. Jazz Pharmaceuticals plc has a 12 month low of $102.86 and a 12 month high of $146.70. The stock has a market capitalization of $6.53 billion, a PE ratio of 21.35, a P/E/G ratio of 1.64 and a beta of 0.58.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 EPS for the quarter, missing the consensus estimate of $3.53 by ($1.55). The business had revenue of $901.98 million for the quarter, compared to the consensus estimate of $938.99 million. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. Equities analysts anticipate that Jazz Pharmaceuticals plc will post 15.35 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on JAZZ. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 27th. Needham & Company LLC lowered their price objective on Jazz Pharmaceuticals from $222.00 to $210.00 and set a “buy” rating for the company in a research note on Thursday, June 20th. UBS Group cut their target price on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a research report on Tuesday. Piper Sandler boosted their target price on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an “overweight” rating in a report on Wednesday, March 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $188.62.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 5,000 shares of the business’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total transaction of $548,250.00. Following the transaction, the executive vice president now owns 36,629 shares in the company, valued at approximately $4,016,369.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.